Luis M. Vence
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Pancreatic and Hepatic Oncology Research
- Immunology top 0.5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
Papers in
- Oncology 33
- Cancer Immunotherapy and Biomarkers 25
- CAR-T cell therapy research 12
- Immunology 28
- Immunotherapy and Immune Responses 19
- Immune Cell Function and Interaction 8
- T-cell and B-cell Immunology 6
- Immune cells in cancer 3
- Co-authors
- Padmanee Sharma (17 shared papers)James Patrick Allison (16 shared papers)Jorge M. Blando (9 shared papers)Sumit Kumar Subudhi (7 shared papers)Jennifer Ann Wargo (3 shared papers)Laszlo George Radvanyi (16 shared papers)Antoni Ribas (2 shared papers)Anu Sharma (2 shared papers)
- Journals
- Clinical Cancer Research (7 papers)Cancer Immunology Research (5 papers)Blood (4 papers)Proceedings of the National Academy of Sciences (3 papers)Nature Medicine (3 papers)
- Partner nations
- United StatesAustraliaNetherlands
In The Last Decade
Luis M. Vence
59 papers receiving 11.4k citations
Luis M. Vence's Hit Papers
Peers
Comparison fields: 5 of 140
- Oncology 6.1k
- Immunology 4.1k
- Biological Psychiatry 205
- Genetics 644
- Molecular Biology 3.9k
Countries citing papers authored by Luis M. Vence
This map shows the geographic impact of Luis M. Vence's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luis M. Vence with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luis M. Vence more than expected).
Fields of papers citing papers by Luis M. Vence
This network shows the impact of papers produced by Luis M. Vence. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luis M. Vence. The network helps show where Luis M. Vence may publish in the future.
Co-authors
The 25 scholars most cited alongside Luis M. Vence, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 59 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients Hit paper breakdown → | 2017 | 3810 |
| 2 | Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade Hit paper breakdown → | 2016 | 817 |
| 3 | Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma Hit paper breakdown → | 2018 | 589 |
| 4 | 1997 | 524 | |
| 5 | VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer Hit paper breakdown → | 2017 | 521 |
| 6 | Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial Hit paper breakdown → | 2013 | 462 |
| 7 | The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis Hit paper breakdown → | 2014 | 460 |
| 8 | Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade Hit paper breakdown → | 2021 | 349 |
| 9 | Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study Hit paper breakdown → | 2017 | 315 |
| 10 | 2018 | 314 | |
| 11 | 2019 | 303 | |
| 12 | 2019 | 287 | |
| 13 | 2019 | 281 | |
| 14 | 2016 | 204 | |
| 15 | 2013 | 202 | |
| 16 | 2017 | 174 | |
| 17 | 2017 | 163 | |
| 18 | 2007 | 153 | |
| 19 | 2019 | 144 | |
| 20 | 2012 | 141 |
About Luis M. Vence
Luis M. Vence is a scholar working on Oncology, Immunology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Genetics, having authored 59 papers that have together received 11.7k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (25 papers), Immunotherapy and Immune Responses (19 papers), CAR-T cell therapy research (12 papers), Immune Cell Function and Interaction (8 papers), Lymphoma Diagnosis and Treatment (6 papers), T-cell and B-cell Immunology (6 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Immune cells in cancer (3 papers). The work is most often cited by research in Oncology (6.1k citations), Immunology (4.1k citations), Biological Psychiatry (205 citations), Genetics (644 citations) and Molecular Biology (3.9k citations). Luis M. Vence has collaborated with scholars based in United States, Australia and Netherlands. Frequent co-authors include Padmanee Sharma, James Patrick Allison, Jorge M. Blando, Sumit Kumar Subudhi, Jennifer Ann Wargo, Laszlo George Radvanyi, Antoni Ribas, Anu Sharma, Hao Zhao and Christopher J. Logothetis. Their work appears in journals such as Clinical Cancer Research, Cancer Immunology Research, Blood, Proceedings of the National Academy of Sciences and Nature Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.